Related Experiment Video
Updated: Jul 3, 2026

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
Mitotic catastrophe and apoptosis induced by docetaxel in hormone-refractory prostate cancer cells
Francesco Fabbri1, Dino Amadori, Silvia Carloni
1Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola (FC), Italy.
Abstract:
Studies performed in different experimental and clinical settings have shown that Docetaxel (Doc) is effective in a wide range of tumors and that it exerts its activity through multiple mechanisms of action. However, the sequence of events induced by Doc which leads to cell death is still not fully understood. Moreover, it is not completely clear how Doc induces mitotic catastrophe and whether this process is an end event or followed by apoptosis or necrosis. We investigated the mechanisms by which Doc triggers cell death in hormone-refractory prostate cancer cells by analyzing cell cycle perturbations, apoptosis-related marker expression, and morphologic cell alterations. Doc induced a transient increase in G2/M phase followed by the appearance of G0/1 hypo- and hyperdiploid cells and increased p21 expression. Time- and concentration-dependent apoptosis was induced in up to 70% of cells, in concomitance with Bcl-2 phosphorylation, which was followed by caspase-2 and -3 activation. In conclusion, Doc would seem to trigger apoptosis in hormone-refractory prostate cancer cells via mitotic catastrophe through two forms of mitotic exit, in concomitance with increased p21 expression and caspase-2 activation.
Insights
Docetaxel (Doc) triggers apoptosis in prostate cancer cells via mitotic catastrophe. This involves cell cycle changes, p21 expression, and caspase activation, leading to programmed cell death.
Area of Science:
- Oncology
- Cell Biology
- Molecular Mechanisms
Background:
- Docetaxel (Doc) is an effective chemotherapy agent for various cancers.
- The precise sequence of events leading to Doc-induced cell death, particularly mitotic catastrophe, remains unclear.
- Understanding Doc's mechanism is crucial for optimizing prostate cancer treatment.
Purpose of the Study:
- To elucidate the mechanisms by which Docetaxel induces cell death in hormone-refractory prostate cancer cells.
- To analyze cell cycle perturbations, apoptosis markers, and morphological changes following Doc treatment.
- To determine if mitotic catastrophe is a terminal event or precedes other cell death pathways.
Main Methods:
- Treatment of hormone-refractory prostate cancer cells with Docetaxel.
- Cell cycle analysis to detect perturbations.
- Assessment of apoptosis-related markers (e.g., Bcl-2 phosphorylation, caspase activation).
- Morphological examination of cellular alterations.
Main Results:
- Docetaxel induced a transient G2/M phase arrest followed by G0/1 diploid cells and increased p21 expression.
- Time- and dose-dependent apoptosis was observed in up to 70% of cells.
- Bcl-2 phosphorylation preceded the activation of caspase-2 and caspase-3.
Conclusions:
- Docetaxel triggers apoptosis in hormone-refractory prostate cancer cells through mitotic catastrophe.
- This process involves distinct forms of mitotic exit, increased p21 expression, and caspase-2 activation.
- The findings clarify the sequence of events in Doc-induced cell death, highlighting its role in apoptosis.
More Related Videos
06:02Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers
Published on: February 20, 2017
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
Related Concept Videos
Drugs that Stabilize Microtubules
Abnormal Proliferation
The Intrinsic Apoptotic Pathway
Drugs that Destabilize Microtubules
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle